Jay B. Lichter

Jay B. Lichter serves as Avelas’ President and Chief Executive Officer. Dr. Lichter is an entrepreneur and seasoned investor in the biotechnology and pharmaceutical arena with over 25 years of expertise in management, scientific research, and business development. Dr. Lichter is an inventor of over 260 patents and patent applications. Dr. Lichter has been either directly responsible for or participated in, licensing or merger and acquisition deals valued in excess of US$5 billion. Dr. Lichter currently serves as a member of the board of directors for eight companies, including Otonomy, Janux Therapeutics, Fortis Therapeutics, Enalza Therapeutics, and Cullinan Mica. Since 2007, Dr. Lichter has been a Managing Director at Avalon Ventures, LLC, an early-stage venture capital fund focused on information technology and life sciences, the Company’s largest stockholder. Dr. Lichter held postdoctoral positions in Human Genetics at Yale University and pharmacogenetics at DuPont Merck Pharmaceutical Co. He obtained his Ph.D. in biochemistry from the University of Illinois at Chicago, and a B.S. from the Univ. of Illinois at Urbana-Champaign.